G
Giancarlo Agnelli
Researcher at University of Perugia
Publications - 623
Citations - 50185
Giancarlo Agnelli is an academic researcher from University of Perugia. The author has contributed to research in topics: Pulmonary embolism & Stroke. The author has an hindex of 91, co-authored 594 publications receiving 45178 citations. Previous affiliations of Giancarlo Agnelli include University of Padua & Novartis.
Papers
More filters
Journal ArticleDOI
Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Adam Torbicki,Arnaud Perrier,Stavros Konstantinides,Giancarlo Agnelli,Nazzareno Galiè,Piotr Pruszczyk,Frank M. Bengel,Adrian J B Brady,Daniel Ferreira,Uwe Janssens,Walter Klepetko,Eckhard Mayer,Martine Remy-Jardin,Jean-Pierre Bassand,Alec Vahanian,John Camm,Raffaele De Caterina,Veronica Dean,Kenneth Dickstein,Gerasimos Filippatos,Christian Funck-Brentano,Irene Hellemans,Steen Dalby Kristensen,Keith McGregor,Udo Sechtem,Sigmund Silber,Michal Tendera,Petr Widimsky,José Luis Zamorano,José Luis Zamorano,Felicita Andreotti,Michael Ascherman,George Athanassopoulos,Johan De Sutter,David Fitzmaurice,Tamás Forster,Magda Heras,Guillaume Jondeau,Keld Kjeldsen,Juhani Knuuti,Irene Lang,Mattie J. Lenzen,Jose Lopez-Sendon,Petros Nihoyannopoulos,Leopoldo Pérez de Isla,Udo Schwehr,Lucia Torraca,Jean-Luc Vachiery +47 more
TL;DR: Non-thrombotic PE does not represent a distinct clinical syndrome but may be due to a variety of embolic materials and result in a wide spectrum of clinical presentations, making the diagnosis difficult.
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Clive Kearon,Susan R. Kahn,Giancarlo Agnelli,Samuel Z. Goldhaber,Gary E. Raskob,Anthony J. Comerota +5 more
TL;DR: This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs.
Journal ArticleDOI
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Barry F. Jacobson,Erich Minar,Jaromir Chlumsky,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Alexander T. Cohen,Scott D. Berkowitz,Bruce L. Davidson,Frank Misselwitz,Gary E. Raskob,Annelise Segers +11 more
TL;DR: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.
Journal ArticleDOI
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli,Harry R. Buller,Alexander T. Cohen,Madelyn Curto,Alexander Gallus,Margot Johnson,Urszula Masiukiewicz,Raphael Pak,John F. Thompson,Gary E. Raskob,Jeffrey I. Weitz +10 more
TL;DR: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.